| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A834 | Vilobelimab Featured | Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc. |
|
| A835 | Avdoralimab Featured | Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research. |
|
| A836 | G2 patent anti-C5aR Featured |
|
|
| A837 | G2_anti-C5aR Featured |
|
|
| A838 | Genentech patent anti-Factor B Featured |
|
|
| A839 | Lampalizumab Featured | Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research. |
|
| A840 | Novelmed patent anti-Properdin Featured |
|
|
| A841 | Regeneron patent anti-RET Featured |
|
|
| A842 | Oxford Bio patent anti-CRTAM Featured |
|
|
| A843 | Cabiralizumab Featured | Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research. |
|
| A844 | Axatilimab Featured | Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases. |
|
| A845 | Emactuzumab Featured | Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) . |
|
| A846 | LY3022855 Featured |
|
|
| A847 | Lenzilumab Featured | Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies. |
|
| A848 | Gimsilumab Featured | Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA). |
|
| A849 | Namilumab Featured | Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis. |
|
| A850 | Plonmarlimab Featured | Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19. |
|
| A851 | Theraclone patent anti-GM-CSF Featured |
|
|
| A852 | Mavrilimumab Featured | Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. |
|
| A854 | Anumigilimab Featured | Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation. |
|
| A855 | CSL patent anti-G-CSFR Featured |
|
|
| A856 | Quavonlimab Featured | Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody. |
|
| A857 | Zalifrelimab Featured | Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling. |
|
| A858 | SY18-VHH-11 Featured |
|
|
| A859 | CAT-2200 Featured | CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001). |
|
| A860 | Ixekizumab Featured | Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis. |
|
| A861 | UCB patent anti-IL-17 Featured |
|
|
| A862 | Anti-CTSS/Cathepsin S Antibody (Fsn0503h) Featured |
|
|
| A863 | Quetmolimab Featured | Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion. |
|
| A864 | Lilly patent anti-Pan-ELR+ Featured |
|
